GammaCan and Tel Ha'Shomer Scientists to Present IgG Colon Cancer Abstract at 5th International Congress on Autoimmunity in Sorr
September 14 2006 - 6:30AM
Business Wire
GammaCan International, Inc. (OTCBB: GCAN) today announced that
scientists from Tel Ha'Shomer Hospital in Tel Aviv and GammaCan
will present an abstract at the 5th Annual Congress on Autoimmunity
in Sorrento Italy from November 29th through December 3rd, 2006.
The study, supported by GammaCan International, under the direction
of Professors Yehuda Shoenfeld, and Miri Blank is entitled "IgG
Decreases Lung Metastatic Potential of Murine (mouse) Colon
Carcinoma." The researchers will present data examining IgG's
(GCAN101) efficacy in inhibiting the proliferation and metastatic
capacity of colon cancer in a mouse model. Results suggesting that
IgG may be considered a supportive therapy for the inhibition of
colon carcinoma metastases will be included in the abstract
discussion. Prof. Jacob Nusbacher, Director of Medical &
Scientific Affairs at GammaCan commented: "This study confirms
other studies that have been done by GammaCan scientists on other
cancers. In the aggregate, these studies lay the groundwork for the
continued development of immunoglobulin-based anti-cancer
therapies, such as we are now doing with our next generation
product, the new anti-melanoma drug, VitiGam." About GCAN101
GCAN101 (standard IgG) is currently completing an open label, 30
patient phase II trial designed to evaluate the efficacy and safety
of IgG therapy in cancer patients who failed all current therapies.
The trial is enrolling patients with colon cancer, melanoma and
prostate cancer. The colon and melanoma arms are fully enrolled.
About VitiGam: VitiGam is GammaCan's second generation intravenous
IgG-based product and a first-in-class anti-cancer immunotherapy.
GammaCan plans on having VitiGam to enter phase I/II testing under
a US IND in the near future after it recently held a pre-IND
meeting with the FDA. VitiGam is being designed to target
metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general. About
GammaCan GammaCan is focusing on the commercialization of an
innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IgG, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IgG works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IgG into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, unforeseen technical
difficulties in developing the technology, the inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early state medical research
and development companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024